Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 535-542

  Rischin, D ^a   Peters, L ^a   Hicks, R ^a   Hughes, P ^a   Fisher, R ^a   Hart, R ^a   Sexton, M ^a   D'Costa, I ^a   Von Roemeling, R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MISONIDAZOLE; TIRAPAZAMINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; HYPOXEMIA; MALE; OROPHARYNX TUMOR; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION SICKNESS; SKIN MANIFESTATION; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

EID: 0035863303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.535     Document Type: Article

References (32)

1. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer
2. Altered fractionation trials in head and neck cancer
3. A Radiation Therapy Oncology Group (RTOG) phase III radomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: Preliminary results of RTOG 0\9003
4. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
6. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial
7. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study
8. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
9. Randomized trial of radiation therapy versus concomitant chemoradiotherapy and radiation therapy for advanced-stage oropharynx carcinoma
10. Radiotherapy and concurrent chemotherapy: A strategy that improves locoregional control and survival in oropharyngeal cancer
11. Concentration of oxygen dissolved in tissues at the time or irradiation as a factor in radiotherapy
12. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
13. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
14. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
15. SR 4233(tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
16. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
17. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
18. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer
19. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancer using (F-18) fluoromisonidazole positron emission tomography
20. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study
21. Clinical evaluation of the hypoxic cytotoxin tirapazamine (SR 4233) with fractionated irradiation: Phase I experience at Stanford University and the University of Alabama
22. An integrated phase I/II analysis of tirazone (tirapazamine) + cisplatin: Safety and efficacy in advanced non-small cell lung cancer (NSCLC) patients
23. Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075)
24. Radiotherapy and hyperbaric oxygen in head and neck cancer: Final report of first controlled trial
25. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitisers
26. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: Results of a randomised clinical trial
27. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
28. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes
29. Tirapazamine: A tumor-specific topoisomerase II inhibitor?
30. Tirapazamine: Laboratory data relevant to clinical activity
31. Characterization of the binding of labeled fluoromisonidazole in cells in vitro
32. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses